Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Ticker
$REGN
Sector
Primary listing
Employees
15,343
Headquarters
Website
Regeneron Metrics
BasicAdvanced
$62bn
14.89
$41.06
0.30
$3.64
0.61%
Price and volume
Market cap
$62bn
Beta
0.3
52-week high
$821.11
52-week low
$503.25
Average daily volume
1.1m
Dividend rate
$3.64
Financial strength
Current ratio
3.565
Quick ratio
4.129
Long term debt to equity
8.612
Total debt to equity
8.612
Dividend payout ratio (TTM)
8.46%
Interest coverage (TTM)
80.06%
Profitability
EBITDA (TTM)
4,382.8
Gross margin (TTM)
43.89%
Net profit margin (TTM)
29.65%
Operating margin (TTM)
25.76%
Effective tax rate (TTM)
14.22%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
6.13%
Return on equity (TTM)
14.55%
Valuation
Price to earnings (TTM)
14.892
Price to revenue (TTM)
4.259
Price to book
1.98
Price to tangible book (TTM)
2.07
Price to free cash flow (TTM)
16.763
Free cash flow yield (TTM)
5.97%
Free cash flow per share (TTM)
36.478
Dividend yield (TTM)
0.60%
Forward dividend yield
0.61%
Growth
Revenue change (TTM)
5.92%
Earnings per share change (TTM)
4.14%
3-year revenue growth (CAGR)
6.45%
10-year revenue growth (CAGR)
12.90%
3-year earnings per share growth (CAGR)
3.75%
10-year earnings per share growth (CAGR)
20.35%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·2 days ago
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
Newsfile Corp·3 weeks ago
Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations
Newsfile Corp·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs